Home Daiichi Sankyo Submits Supplemental New Drug Application In Japan For LIXIANA (Edoxaban Tosilate Hydrate) For New Indications
 

Keywords :   


Daiichi Sankyo Submits Supplemental New Drug Application In Japan For LIXIANA (Edoxaban Tosilate Hydrate) For New Indications

2013-12-30 06:22:57| drugdiscoveryonline News Articles

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its oral, once-daily direct factor Xa-inhibitor LIXIANA® (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry of Health, Labour and Welfare

Tags: new japan application drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
More »